Disclosed are means of protecting signaling integrity of T cells in cancer patients through reduction of neutrophil and other cellular induced oxidative stress. In one embodiment the FDA approved drug Mucomyst is administered at a concentration of 50-150 mg/kg to increase expression of T cell receptor (TCR)-zeta chain in patients with cancer. In other embodiments enhancement of CAR-T cell therapy is performed through modulation of inflammatory and oxidative stress in a tumor bearing patient.
